Alteogen (196170) Fundamentals 2026 — P/E 110.3x, Revenue Analysis | SniperIQ
Alteogen (196170) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩14.34T, trading at ₩268000.00 on the KOE. This SniperIQ fundamentals page covers Alteogen's valuation (P/E 110.3x, P/B 28.4x), profitability (net margin 63.7%), revenue (₩215.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Alteogen's market cap?
Alteogen (196170) has a market capitalization of approximately ₩14.34T, trading at ₩268000.00 on the KOE. Market cap moves with the live share price.
What is Alteogen's P/E ratio?
Alteogen's trailing twelve-month P/E ratio is 110.3x, with a price-to-book (P/B) of 28.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Alteogen?
Alteogen runs a net profit margin of 63.7%, a gross margin of 82.8%, and an operating margin of 41.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Alteogen generate?
Alteogen reported revenue of ₩215.9B for fiscal year 2025, with net income of ₩141.7B and earnings per share (EPS) of 2652.97. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Alteogen pay a dividend?
Alteogen offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Alteogen financially healthy?
Alteogen carries a debt-to-equity ratio of 0.20x and a current ratio of 2.41x, with a market beta of 0.94. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Alteogen a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Alteogen (196170) the key facts are: market cap ₩14.34T, P/E 110.3x, revenue ₩215.9B, 52-week range 253000-569000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Alteogen's full fundamentals live
Get Alteogen's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.